Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 77

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 77
---
 million during the three months ended September 30, 2025, compared to $2.2 million during the three months
ended September 30, 2024. The increase in general and administrative expenses was mainly due to the Company incurring $0.6 million higher
stock-based compensation during 2025, partially offset by $0.2 million lower professional fees.

Other Expense, net

During the three months ended
September 30, 2025, the Company recorded $1.0 million of other income, of which approximately $0.6 million was gain on forgiveness of
payables from two vendors and approximately $0.4 million was due to interest income.

During the three months ended
September 30, 2024, the Company’s other income consisted of interest income partially offset by interest expense.

30

Comparison of the Nine Months Ended September
30, 2025 and 2024

The following table summarizes
our results of operations for the periods indicated:

    Nine Months Ended September 30,  

    (in thousands) 
    2025  
    2024  
    Change 
  
    Revenues 
    $50  
    $14  
    $36 
  
    Operating expenses: 

    Research and development 
     18,330  
     25,813  
     (7,483)
  
    General and administrative 
     7,115  
     7,369  
     (254)
  
    Impairment of acquired in-process research and development intangible assets 
     16,514  
     -  
     16,514 
  
    Total operating expenses 
     41,959  
     33,182  
     8,777 
  
    Loss from operations 
     (41,909) 
     (33,168) 
     (8,741)
  
    Other income, net 
     1,240  
     304  
     936 
  
    Net loss 
    $(40,669) 
    $(32,864) 
    $(7,805)

Revenues

During the nine months ended
September 30, 2025, the Company recognized revenue from a license agreement that was terminated during 2025. During the nine months ended
September 30, 2024, the Company recognized revenue from the sale of MSC’s.

Research and Development

Research and